Abstract
INTRODUCTION
Wait times in the treatment of breast cancer have increased over the past 20 years, [1] [2] [3] [4] in part as a result of the growing complexity of breast cancer management, including additional testing conducted to help guide treatment decisions. 3, 5 Among patients with early-stage estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the Oncotype DX Recurrence Score (RS; Genomic Health, Redwood City, CA), a multigene diagnostic test that provides 10-year estimates for risk of breast cancer recurrence and the potential benefit of chemotherapy, is used by oncologists to assist in adjuvant treatment decisions and is included in all major breast cancer clinical guidelines. [6] [7] [8] Incorporating Oncotype DX testing into clinical practice has been shown to limit unwarranted chemotherapy use, leading to decreased patient morbidity and reduced health care costs, 9 -12 yet frequently introduces delays to treatment decision making and chemotherapy initiation. 3, 5 Vandergrift et al 3 reported that Oncotype DX testing was associated with a 2.2-week increase in time to chemotherapy initiation. Similarly, we previously reported that patients undergoing RS testing were seven times more likely to wait longer than 6 weeks from last definitive breast surgery (LDS) to begin chemotherapy. 5 With emerging evidence suggesting that delays to adjuvant chemotherapy may adversely affect clinical outcomes and contribute to increased patient stress and anxiety, [13] [14] [15] [16] [17] [18] [19] [20] cancer centers are faced with the challenge of developing institutional processes to mitigate the delays that additional tests impose on the patient's treatment timeline. As part of a multidisciplinary quality improvement initiative to address timeliness of care for patients with breast cancer at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC), this study sought to assess the impact of implementing standardized Oncotype DX ordering criteria and streamlined workflows between medical and surgical oncology and pathology on the turnaround time (TAT) to RS testing and timeliness to chemotherapy initiation.
METHODS

Setting
We examined the care of women treated for breast cancer at DF/BWCC, an NCI-designated comprehensive cancer center with . 4,000 unique new patients with breast cancer annually. The DF/BWCC uses a multidisciplinary clinic model, by which patients with early-stage invasive breast cancer are seen at initial consultation by both a medical oncologist and a surgical oncologist.
Quality Improvement Methodology (DMAIC) Define After a review of retrospective data highlighting factors associated with adjuvant chemotherapy delays in our practice, 5 breast oncology leadership identified the opportunity to expedite adjuvant chemotherapy initiation among patients undergoing Oncotype DX testing. The team established a time-to-treatment target of 28 days from LDS to chemotherapy initiation.
Measure
To assess the impact of our interventions, a separate data set of patients who had Oncotype DX ordered between January 2014 and November 2016 was developed to measure the following milestones: days between surgery and Oncotype DX order, days between surgery and Oncotype DX result date, and days between LDS and chemotherapy initiation. LDS was defined as the breast surgery immediately before the start of chemotherapy, including re-excisions, mastectomy, and axillary lymph node procedures. Patients undergoing breast surgery outside DF/ BWCC, male patients, and patients who received preoperative therapy were excluded.
Analyze
Through facilitated meetings with medical oncologists, surgeons, pathologists, and administrative managers and staff, barriers to timely ordering of Oncotype DX were identified. These included lack of standard ordering criteria, absence of a routine process for pathology result communication between surgical and medical oncology teams, variation in the timing of when Oncotype DX was ordered, no standard method to order Oncotype DX, and use of paper-based ordering.
Improve
The multidisciplinary team focused on developing solutions to expedite Oncotype DX ordering. Through a consensus process among medical oncology experts in our center, the team developed criteria for reflex Oncotype DX ordering for any patient # 65 years of age with ER-positive/HER2-negative breast cancers and the following tumor characteristics: T1cN0 (grade 2 or 3), T2N0 (grade 1 or 2), or T1/T2N1 (grade 1 or 2). The criteria were created with the goal of identifying patients for whom the majority of clinicians would typically consider Oncotype DX testing for adjuvant chemotherapy decision making and for whom the test results could alter management. In addition, the responsibility for ordering Oncotype DX among patients whose tumor characteristics met criteria was shifted from medical to surgical oncology. For cases meeting criteria, Oncotype DX requests would be made by the surgeon within 1 day of the pathology review being complete and before the patient's postoperative appointment (Fig 1) . For all cases, a member of the surgical team would communicate postoperative pathology results to the medical oncologist in real time, to allow medical oncologists to order Oncotype DX for cases falling outside the criteria, if appropriate.
A streamlined pathology system for receiving and processing RS requests was developed by creating a centralized email address for all requests, and paper orders were replaced with online ordering through the Genomic Health portal. Lastly, all clinicians were given access to receive RS results electronically, and a uniform process was developed to scan the results into the electronic medical record to ensure that the multidisciplinary care team had access to the results. The workflows were shared with clinicians and administrative staff across breast medical and surgical oncology and pathology departments via faculty/staff meetings and e-mail communications. 
Control
Following implementation of reflex Oncotype DX ordering and the new workflows, data were collected to compare baseline TAT with the postintervention period. During the initial rollout of the interventions, information was shared with medical and surgical oncologists and pathologists regarding process compliance, including feedback to individual providers if Oncotype DX orders were not placed appropriately or in a timely manner. Biweekly meetings with the multidisciplinary project team were held to identify process issues and to share preliminary intervention results.
RESULTS
A total of 720 consecutive women with breast cancer underwent Oncotype DX testing following breast surgery at DF/ BWCC between January 1, 2014 and November 28, 2016 (n = 472, baseline cohort; n = 248, postintervention cohort). The mean age was 55 years (range, 27 to 77 years), 87% were white, and 77.6% had private insurance. The proportion of patients who received chemotherapy after Oncotype DX testing was 17.8% in the baseline and 16.1% in the postintervention cohorts. Among patients in the postintervention cohort who received chemotherapy, three patients (8%) had an RS , 18, 26 patients (65%) had an RS between 18 and 30, and 11 patients (28%) had an RS . 30.
The mean number of days between surgery and Oncotype DX order was 20.2 for the baseline period and 12.9 postintervention (P , .001; Table 1 ). The mean number of days between surgery and receipt of Oncotype DX results was 28.5 and 22.2 in the baseline and postintervention groups, respectively (P , .001). Among patients who received adjuvant chemotherapy, a 6.4-day decrease in the mean number of days from LDS to chemotherapy initiation between baseline (n = 84) and postintervention (n = 40) was also observed (P = .004). The proportion of patients who initiated chemotherapy within 42 days of LDS increased from 52% to 75% postintervention.
DISCUSSION
Our quality improvement project exposed multiple barriers to timely Oncotype DX ordering that were within provider and institutional control. Through establishing ordering criteria, streamlined workflows, and role accountabilities among the multidisciplinary care team, our study provides a straightforward approach to reducing unwarranted delays to chemotherapy initiation among patients with breast cancer undergoing Oncotype DX testing.
Through implementing Oncotype DX reflex testing and shifting the responsibility of ordering to the breast surgeon, patients who initiated chemotherapy postintervention experienced a statistically significant and clinically meaningful reduction in wait times. From the perspective of patient satisfaction and operational efficiency, we believe that the reduction of nearly 1 week in mean time to chemotherapy initiation represents a noteworthy improvement in care quality. Furthermore, we anticipate that among the 83.9% of patients who did not receive adjuvant chemotherapy, obtaining RS results earlier allowed this group to initiate hormonal or radiation therapy in a timelier manner and probably decreased the stress and anxiety associated with waiting for test results. Our study is subject to several limitations. Because the focus of this study was on measuring the impact of the intervention on care timeliness, tumor characteristics were not abstracted. Therefore, we cannot compare differences between the pre-and postintervention cohorts or stratify the TAT on the basis of whetherthepatientsmetthereflexcriteria.Inthefuture,wehope to obtain the tumor characteristics to elucidate any differences between the groups and to assess the proportion of patients whosetumorsmeet orfalloutsidethereflexcriteriainaneffortto possibly refine our criteria. We also did not document time to hormonal therapy initiation or start of radiation therapy. Therefore, we are unable to determine the impact of our intervention on the time to initiation of other treatment modalities. Lastly, weare unable todeterminetheimpact of the time savings on patient and/or provider satisfaction, cost savings to patients or the institution, or the effect on clinical outcomes. In future work, we hope to address these important topics.
Despite these limitations, our study demonstrates that improvements in timeliness to chemotherapy initiation among patients with ER-positive/HER2-negative early-stage breast cancer can be achieved through standardized workflows within multidisciplinary care teams and that these interventions can be transferred to other institutions. In an era of increasing wait times for treatment, cancer centers should invest in efforts to reduce unwarranted care delays.
